Human Genome Sciences, Inc. (HGSI) and GlaxoSmithKline PLC (GSK,GSK.L) announced Thursday that BENLYSTA has been granted a priority review designation by the U.S. Food and Drug Administration or FDA. The regulatory body granted the designation to BENLYSTA as a potential treatment for systemic lupus erythematosus.
A priority review designation is granted to drugs that, if approved, offer major advances in treatment or provide a treatment where no adequate therapy exists. The FDA has assigned a Prescription Drug User Fee Act target date of December 9, 2010.
The Biologics License Application was submitted to the FDA on June 9, 2010, and GSK submitted a Marketing Authorization Application to the European Medicines Agency on June 4, 2010.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.